Patch Biosciences

Acquired

Machine-designed sequences for safer, more effective gene therapy

Albany, United States · Founded 2020

Headquarters
Albany, New York
Employees
1–10
Founded
2020
Business Model
B2B
Website
patch.bio
Last Round
SeedSep 2020
Rounds
1
Acquired by
Ginkgo BioworksFeb 2024

About

Patch Biosciences was a synthetic biology and machine learning company that built an AI platform for sequence design to engineer more effective, specific, and durable genetic medicines. The company developed machine learning models and downstream assays to engineer synthetic promoters and untranslated regions (UTRs) for gene therapy, cell therapy, and RNA therapeutics applications. Backed by Andreessen Horowitz Bio+Health, Casdin Capital, and S32, Patch was acquired by Ginkgo Bioworks in February 2024, with its AI/ML capabilities integrated into Ginkgo's genetic medicine platform to accelerate programs for biopharma partners including Pfizer and Biogen.

Summary

Patch Biosciences is a Healthcare company based in Albany, United States, founded in 2020. Its most recent funding was a Seed round in Sep 2020. Investors include Andreessen Horowitz, Section 32 and Casdin Capital.

Tech & App Stack

1 technologies & apps tracked

Every product and vendor across these categories, with where each signal came from.

Create a free account with 25 free credits every month, no card needed, to unlock the full tech & app stack, funding history, and valuations.

Funding History

AcquisitionFeb 2024

Sign up to see all 2 rounds

Seed through Acquisition — per-round amounts, valuations, and who invested in each round.

Investors

Similar Companies

Your company? Embed this profile

Add the live badge to your site — it stays current as your funding data updates.

Patch Biosciences on Indexed.vc
<a href="https://indexed.vc/companies/patch-biosciences"><img src="https://indexed.vc/api/badge/company/patch-biosciences" alt="Patch Biosciences on Indexed.vc" width="260" height="76" /></a>